Company Profile

Yaso Therapeutics Inc (AKA: Yaso Biotechnology Inc)
Profile last edited on: 9/27/2017      CAGE: 4XQ21      UEI: GHMJR4AX38G9

Business Identifier: Contraceptives and products for STI prevention
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

20860 N Tatum Boulevard Suite 300 Office 320
Phoenix, AZ 85050
   (480) 771-4058
Location: Multiple
Congr. District: 06
County: Maricopa

Public Profile

Yaso is an early stage drug development company developing a line of prophylactic products for women and men designed to prevent sexually transmitted disease and unintended pregnancy. With a proven track record of success in women's reproductive health products, the firms has the worldwide license for a unique polymeric drug with which the firm is currently developing several dosage forms for preclinical evaluation. Yaso is dedicated to the discovery and development of products to prevent the spread of sexually transmitted infections and sexually transmitted HIV. The firm's current research is in the field of microbicides. The firm has the worldwide license to a drug, PPCM, that promises to prevent infections during sexual intercourse. PPCM, is the only drug under development that promises to be both contraceptive and prevent viral and bacterial STIs.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 1 NIH $298,521
Project Title: Preparation and submission of an IND for PPCM Gel contraceptive
2020 2 NIH $3,951,348
Project Title: Preclinical development of PPCM vaginal contraceptive to submit IND
2014 2 NIH $2,285,612
Project Title: Pre-Clinical Development of Ppcm Vaginal Microbicide
2006 1 NIH $152,196
Project Title: Development of SAMMA based vaginal microbiocide

Key People / Management

  Mary B Weitzel -- CEO and President

  Rhonda Baird -- VP of Finance/Treasurer

  Barbara Best North -- Medical Director

  Michael J Oldham -- Co-Founder

  Donald Waller -- Vice President Research & Development (Acting)